Introduction
Lencioni R et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Gastrointestinal Cancers Symposium 2024;Abstract LBA432.
Ahmed Omar Kaseb, MD, CMQ
Chan SL et al. Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC). ESMO GI 2023;Abstract 147P.
Cheon J et al. Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial. Gastrointestinal Cancers Symposium 2023;Abstract TPS634.
Chon HJ et al. High atezolizumab antidrug antibody levels are associated with unfavorable clinical outcomes and diminished T cell responses following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma. ASCO 2022;Abstract 4105.
Finn RS et al. Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). ESMO 2022;Abstract LBA34.
Gile J et al. Outcome of receiving lenvatinib following immunotherapy in patients with advanced hepatocellular carcinoma. Gastrointestinal Cancers Symposium 2023;Abstract 507.
Haber PK et al. Evidence-based management of hepatocellular carcinoma: Systematic review and meta-analysis of randomized controlled trials (2002-2020). Gastroenterology 2021;161(3):879-98. Abstract
Jackson R et al. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: A meta-analysis of randomized phase III trials. J Clin Oncol 2017;35(6):622-8. Abstract
Joerg V et al. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study. Hepatol Commun 2023;7(11):e0302. Abstract
Kelley RK et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23(8):995-1008. Abstract
Kudo M et al. Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: A post hoc analysis of the phase III IMbrave150 study. Liver Cancer 2023;12(5):479-93. Abstract
Kudo M et al. IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC. ESMO GI 2020;Abstract 169P.
Palmer M et al. Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma. Gastrointestinal Cancers Symposium 2023;Abstract 559.
Yau T et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncology 2020;1;6(11):e204564. Abstract
Zhu AX et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16(7):859-70. Abstract
Arndt Vogel, MD, PhD
Bouattour M et al. Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer. Gastrointestinal Cancers Symposium 2023;Abstract 531.
Kelley RK et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;3;401(10391):1853-65. Abstract
Klein O et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers. JAMA Oncology 2020;6(9):1405-9. Abstract
Martin-Serrano MA et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 2023;72(4):736-48. Abstract
Oh D-Y et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. Gastrointestinal Cancers Symposium 2022;Abstract 378.
Oh D-Y et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1(8). Abstract
Oh D-Y et al. Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC). ASCO 2020;Abstract 4520.
Piha-Paul SA et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 2020;147(8):2190-8. Abstract
Taylor MH et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 2020;38(11):1154-63. Abstract
Vogel A et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34(2):127-40. Abstract
Vogel A et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). ASCO 2022;Abstract 4075.
Vogel A, Saborowski A. Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer Treat Rev 2020;82:101946. Abstract